HCPLive Network
PERSONAL FINANCE

Celgene Sell Off “Overdone”

Laura Joszt | Friday, June 22, 2012
While Onyx Pharmaceuticals is flying high on good news for its blood cancer drug, Celgene wasn’t quite so lucky. Celgene’s stock took a big hit on Thursday when it withdrew its application for Revlimid. And by the end of the week, the stock hadn’t recovered much.
 
When the European Medicine’s Agency (EMA) indicated it wanted more data on Revlimid’s application to be used on newly diagnosed multiple myeloma patients and as a maintenance therapy, Celgene withdrew the application. When news broke, its stock dropped 11.65% at the opening bell on Thursday.
 
By the end of the day Friday, the stock had only recovered slightly, up 3.68%, but still down by 8.19% over where it had closed on Wednesday afternoon.
 
 
However, investors might be a little trigger happy with Celgene. For one, the company could still resubmit to EMA. Also, a trial combining Onyx’s Kyprolis with Revlimid and Dexa revealed that patients had a 98% response rate and a 92% progression-free survival rate.
 
Revlimid is already an approved blood cancer drug — the company is simply looking to expand its use. Plus, the drug could also have a number of other uses, such as lymphoma and CLL. Another Celgene drug could be approved for a second use this year.
 
According to SeekingAlpha, the sell off could nicely benefit investors who take advantage of it to buy up shares. Robert W. Baird released a note that it believed the sell off was overdone. The wealth management company has set a price target at $78.
 
The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.
 
Read more:


RELATED ARTICLES
The true cost of Obamacare was recently revealed in the pages of a new Congressional Budget Office report. The total bill for the president’s program is estimated to reach $1.9 trillion over the next 10 years.
The US economy is growing at a pace not seen in the last decade, yet the stock market is caught in a web of uncertainty that has little chance of clearing up in the months ahead. In such times, the prudent choice is to stick with quality stocks like these.
Big data is increasingly having an impact on the way physicians practice medicine. Now a new tool is leveraging crowdsourced data to help doctors make smarter career choices.
RECENT CLINICAL ARTICLES
The CDC has deemed the 2014-2015 flu season as reaching epidemic proportions. In part 2 of our flu series interview with Rob Pedowitz, DO, from CentraState Healthcare System, discusses what makes it an epidemic as well as issues with the current flu vaccine.
When diagnosing patients with the flu many doctors go with their instincts and symptoms over tests that have not always been able to diagnose various strains of the virus.
The 2014-2015 flu season has been one of the worst in recent years due to several factors. Robert Pedowitz, DO, of the CentraState Healthcare System explains some of the issues facing patients and doctors during the most recent epidemic.